Publicacións en colaboración con investigadores/as de Hospital Universitario Marqués de Valdecilla (94)

2024

  1. Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review

    Frontiers in Neurology , Vol. 15

2023

  1. Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort.

    Multiple Sclerosis and Related Disorders, Vol. 75

  2. CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome

    Neurology, Vol. 100, Núm. 23, pp. E2386-E2397

  3. Changes in Principal Caregiver Mood Affects the Mood of the Parkinson's Disease Patient: The Vicious Cycle of Illness

    Journal of Parkinson's disease, Vol. 13, Núm. 2, pp. 219-231

  4. Clinical utility of a personalized and long-term monitoring device for Parkinson's disease in a real clinical practice setting: An expert opinion survey on STAT-ON™

    Neurologia, Vol. 38, Núm. 5, pp. 326-333

  5. Cognitive impairment and dementia in young onset Parkinson’s disease

    Journal of Neurology, Vol. 270, Núm. 12, pp. 5793-5812

  6. Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study

    Neurology and Therapy, Vol. 12, Núm. 6, pp. 2177-2193

  7. Epidemiology of ataxia and hereditary spastic paraplegia in Spain: a cross-sectional study

    Neurologia, Vol. 38, Núm. 6, pp. 379-386

  8. Exploring the Spectrum of RHOBTB2 Variants Associated with Developmental Encephalopathy 64: A Case Series and Literature Review

    Movement Disorders Clinical Practice, Vol. 10, Núm. 11, pp. 1671-1679

  9. Falls Predict Acute Hospitalization in Parkinson's Disease

    Journal of Parkinson's disease, Vol. 13, Núm. 1, pp. 105-124

  10. Prevalence and Factors Associated with Drooling in Parkinson's Disease: Results from a Longitudinal Prospective Cohort and Comparison with a Control Group

    Parkinson's Disease, Vol. 2023

  11. Response to levodopa in Parkinson's disease over time. A 4-year follow-up study

    Parkinsonism and Related Disorders, Vol. 116

  12. Risk of Cognitive Impairment in Patients With Parkinson’s Disease With Visual Hallucinations and Subjective Cognitive Complaints

    Journal of Clinical Neurology (Korea), Vol. 19, Núm. 4, pp. 344-357

  13. Sex Differences in Motor and Non-Motor Symptoms among Spanish Patients with Parkinson’s Disease

    Journal of Clinical Medicine, Vol. 12, Núm. 4

  14. Staging Parkinson's Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life

    Journal of Parkinson's disease, Vol. 13, Núm. 3, pp. 379-402

  15. Staging Parkinson's disease according to the MNCD classification correlates with caregiver burden

    Brain and Behavior, Vol. 13, Núm. 12

  16. Suicidal ideation among people with Parkinson's disease and comparison with a control group

    International journal of geriatric psychiatry, Vol. 38, Núm. 5, pp. e5919

2022

  1. An International Perspective on Preceding Infections in Guillain-Barré Syndrome: The IGOS-1000 Cohort

    Neurology, Vol. 99, Núm. 12, pp. E1299-E1313

  2. Calcitonin gene–related peptide in migraine: from pathophysiology to treatment

    Neurologia, Vol. 37, Núm. 5, pp. 390-402

  3. Clinical and structural brain correlates of hypomimia in early-stage Parkinson's disease

    European Journal of Neurology, Vol. 29, Núm. 12, pp. 3720-3727